DeborahMulfordMD

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Associate Professor of Clinical Medicine

Dr. Mulford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
601 Elmwood Ave
# Box
Rochester, NY 14642
Phone+1 585-275-0784

Fax+1 585-273-5761

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
NYU Grossman School of MedicineResidency, Internal Medicine, 1999 - 2002
University of Rochester School of Medicine and DentistryClass of 1999

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

PubMed

2 citations
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Brian T Hill, Shuo Ma, Clive S Zent, Andrea M Baran, Danielle S Wallace
Blood Advances. 2024-01-23
Patient-reported impact of symptoms in lung cancer (PRISM-LC).
Anika Varma, Jennifer Weinstein, Jamison Seabury, Spencer Rosero, Christine Zizzi
Translational Lung Cancer Research. 2023-07-31
46 citations
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.
Delphine Lissa, Nobuyuki Takahashi, Parth Desai, Irena Manukyan, Christopher W Schultz
Nature Communications. 2022-04-19

Abstracts/Posters

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Deborah A Mulford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019